Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 mai 2015 16h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports First Quarter 2015 Financial Results

EMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the first quarter of 2015. "In 2015, we have made continued...
10 avr. 2015 08h30 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease

EMERYVILLE, Calif., April 10, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102...
09 avr. 2015 16h01 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference

EMERYVILLE, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2015 Needham...
31 mars 2015 16h01 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Issued Patent

EMERYVILLE, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that United States Patent and Trademark Office (USPTO) issued US Patent No. 8,987,333...
03 mars 2015 16h02 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Reports Fiscal 2014 Financial Results

EMERYVILLE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the year ended December 31, 2014. "We made significant progress...
09 févr. 2015 16h01 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published in Movement Disorders

EMERYVILLE, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results from its Phase 2/3 clinical study of ADS-5102 (EASED) have been published...
11 janv. 2015 19h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers

EMERYVILLE, Calif., Jan. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas,...
08 janv. 2015 16h02 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis

EMERYVILLE, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings...
02 déc. 2014 09h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Issued Six Additional U.S. Patents

EMERYVILLE, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US...
18 nov. 2014 12h00 HE | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference

EMERYVILLE, Calif., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 26th Annual...

Page précédente